Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

First Motion for Exclusivity Period Extension Filed by Immune Pharmaceuticals, Inc.

05/21/2019 | 12:00am EST

Immune Pharmaceuticals, Inc. filed a motion in the US Bankruptcy Court seeking the extension of its exclusivity periods on May 21, 2019. As per the motion, the debtor seeks to extend its exclusivity periods for both, to file a plan and to solicit votes on a plan, by 90 days i.e. up to September 15, 2019 and November 14, 2019, respectively. The debtor’s current exclusivity period and solicitation period would expire on June 17, 2019 and August 16, 2019, respectively.


ę S&P Capital IQ 2019
All news about IMMUNE PHARMACEUTICALS, INC.
04/13IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in..
AQ
04/12IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form..
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
More news
Chart IMMUNE PHARMACEUTICALS, INC.
Duration : Period :
Immune Pharmaceuticals, Inc. Technical Analysis Chart | IMNPQ | US45254C2008 | MarketScreener
Managers and Directors
Adeel Ahmed-Daudpota President & Chief Executive Officer
Devin J. Shaw Chief Financial Officer
John Zhang Vice President-Research & Development
John A. Neczesny Independent Director
Jeffrey Paley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.-90.00%0
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049